BRAIN Biotech AG financial highlights
| in € million | 2022/23 | 2021/22 | 2020/21 |
|---|---|---|---|
| Consolidated income statement data: | |||
| Revenue | 55.3 | 49.5 | 38.4 |
| Total operating performance | 57.1 | 53.1 | 40.7 |
| EBITDA | –0.8 | –1.3 | –2.5 |
| Adjusted EBITDA | 0.4 | –0.1 | –2.1 |
| Net loss for the reporting period | –8.1 | –6.3 | –4.7 |
| Consolidated balance sheet data: | |||
| Total equity | 23.0 | 34.2 | 41.8 |
| Equity ratio (in %) | 32.4% | 43.9% | 53.8% |
| Total assets | 70.9 | 78.0 | 77.7 |
| Consolidated cash flow data: | |||
| Cash flows from operating activities | –4.2 | –1.5 | –3.9 |
| Cash flows from investing activities | 0.6 | –12.7 | –2.2 |
| Cash flows from financing activities | 0.5 | –2.0 | 11.6 |